Corcept Therapeutics (NASDAQ:CORT) shares were trading lower Tuesday after the company reported preliminary fourth-quarter sales results and issued fiscal year 2021 sales guidance.
Corcept Therapeutics Inc is engaged in the discovery, development, and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.
Corcept Therapeutics shares were trading at $28.29. The stock has a 52-week high of $30.98 and low of $9.70.
